Interdisciplinary Collaboration for the Management of Severe Alopecia Areata in Patients with Comorbidities Grant

Interdisciplinary Collaboration for the Management of Severe Alopecia Areata in Patients with Comorbidities Grant

Status: ACTIVE
Funder: Pfizer, Inc.
Amount: Up to US $100,000
Last Updated: August 03, 2025

Summary

This program aims to enhance educational initiatives for managing Alopecia Areata (AA) in patients with comorbidities. By addressing gaps in knowledge and practice, it supports symposia at US dermatology congresses focused on severity assessment, treatment options, and interdisciplinary collaboration among healthcare professionals. The goal is to improve care for both adult and adolescent patients, emphasizing the pathophysiology of AA and the efficacy of kinase inhibitors in treatment.

Overview

This competitive program seeks to support educational projects that focus on addressing knowledge and practice gaps specific to the diagnosis, severity assessment, treatment, and overall care management of Alopecia Areata (AA) for the adult and adolescent (aged 12-17 years) patient population with comorbidities. Project Types and Area of Interest The landscape of treatment for alopecia areata is advancing, with more evidence and breakthrough therapeutic options available to patients. Through this RFP, it is our intent to support educational symposia at major US dermatology congresses that focus on addressing knowledge and practice gaps specific to severity assessment, treatment, and overall care management of adult and adolescent(aged 12-17 years) patients suffering from alopecia areata respectively. Potential applicants are encouraged to identify and address the educational needs, barriers and knowledge gaps with focus on: Improving knowledge comprehension through active involvement of diagnosis, severity assessment, treatment, and overall care management of AA in patients with comorbidities.The pathophysiology of AA with specific focus on immunologic pathways and the influence of  comorbidities.Burden of disease, clinical manifestations, and severity assessment of AA in patients with comorbidities.The use of kinase inhibitor for the treatment of severe AA in patients with comorbidities. Projects that will be considered for Pfizer support should focus on meeting the educational needs of the dermatologists, nurses, nurse practitioners, physician assistants on managing pediatric or adult AA along with interdisciplinary collaboration including other specialists to optimize patient care.

Eligibility

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

Application Details

Pfizer Independent Medical Education Grant
Request for Proposals
Competitive Grant Program – Pfizer Internal Review Process
Interdisciplinary Collaboration for the
Management of Severe Alopecia Areata in
Patients with Comorbidities
Overview
This competitive program seeks to support educational projects that
focus on addressing knowledge and practice gaps specific to the
diagnosis, severity assessment, treatment, and overall care
management of Alopecia Areata (AA) for the adult and adolescent
(aged 12-17 years) patient population with comorbidities.
Geographic Scope
United States
Project Types and Area of Interest
The landscape of treatment for alopecia areata is advancing, with
more evidence and breakthrough therapeutic options available to
patients. Through this RFP, it is our intent to support educational
symposia at major US dermatology congresses that focus on
addressing knowledge and practice gaps specific to severity
assessment, treatment, and overall care management of adult and
adolescent (aged 12-17 years) patients suffering from alopecia areata
respectively.
Key Milestones
• Application submission deadline: September 16, 2025
• Anticipated decision notification date: November 2025
• Anticipated projects start date: January 2026
Funding Range and Project Length
Individual projects requesting up to $100,000 USD will be considered.
Maximum project length is 12 months.

I. Eligibility
Geographic Scope/Location of Project:
United States
•
Applicant Eligibility Criteria:
• The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional
schools; healthcare institutions (both large and small); professional organizations/medical societies;
medical education companies; and other entities with a mission related to healthcare professional
education and/or healthcare improvement.
• Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an
independent group of physicians not affiliated with a hospital, academic institution, or professional
society).
• If the project involves multiple departments within an institution and/or between different institutions /
organizations / associations, all institutions must have a relevant role and the requesting organization
must have a key role in the project.
• The applicant must be the project/program lead or an authorized designee of such individual (e.g.,
project/program lead’s grant coordinator).
• The project/program lead must be an employee or contractor of the requesting organization.
• Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We
strongly recommend that applicants confirm this with their organization or institution prior to submitting
an application. Grants awarded to organizations that are subsequently found to be unable to accept
funding directly from Pfizer Inc. may be subject to rescission.
• For projects offering continuing education credit, the requesting organization must be accredited.
II. Requirements
Primary Area of Interest:
Dermatology - Alopecia Areata – KG
▪
General Area of Interest for this RFP:
Educational projects eligible for Pfizer support should focus on the care and treatment of adults and
adolescents (ages 12-17) who have comorbidities and are receiving kinase inhibitors for severe
alopecia areata.
Potential applicants are encouraged to identify and address the educational needs, barriers and
knowledge gaps with focus on:
Improving knowledge comprehension through active involvement of diagnosis, severity
▪
assessment, treatment, and overall care management of AA in patients with comorbidities.
The pathophysiology of AA with specific focus on immunologic pathways and the influence of
▪
comorbidities.
Burden of disease, clinical manifestations, and severity assessment of AA in patients with
▪
comorbidities.
The use of kinase inhibitor for the treatment of severe AA in patients with comorbidities.
▪
Projects that will be considered for Pfizer support should focus on meeting the educational needs of the
dermatologists, nurses, nurse practitioners, physician assistants on managing pediatric or adult AA
along with interdisciplinary collaboration including other specialists to optimize patient care.
2

The project design should focus on:
Educational projects in live and/or virtual formats.
▪
A complete knowledge gap and needs assessment and a clear explanation of how the grant will
▪
help close this gap.
Description on how the learning will be applied to improve treatment plans in clinical practice.
▪
Use of evidence-based tools to improve knowledge translations into outcomes.
▪
There is a preference for accredited learning activities. Additionally, the project should consider adding
the following:
Calculation of patient impact (including details of how it was calculated) and anticipated number of
▪
learners.
Knowledge and competence method of evaluation, with meaningful measurements: (i.e.: pre-post
▪
test assessments).
Impact on higher levels of outcomes: performance, patient health, community health.
▪
Practice change in behavior- short- and long-term impact and barriers to implementing practice
▪
changes.
Potential long-term HCP engagement for sustainable competence.
▪
Please find a full description of the proposals’ requirements in the appendix section of this document.
It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or
diagnostic agents will not be considered.
Target Audience:
The target audience for the project should include dermatologists, pediatric dermatologists, nurses,
▪
nurse practitioners, and/or physician assistants who treat AA.
Expected Approximate Monetary Range of Grant Applications:
Individual projects requesting up to $100,000 will be considered. The funding of 1-3 projects is
▪
anticipated.
Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy),
▪
and indirect costs.
Key Dates:
RFP release date: August 1, 2025
▪
Grant Application due date: September 16, 2025
▪
Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
▪
Anticipated Grant Award Notification Date: November 2025
▪
Grants will be distributed following a fully executed agreement.
▪
Anticipated Project Start and End Dates: January 2026 to December 2026
▪
How to Submit:
Important Note: Please read this section carefully since applications submitted not following these
instructions will not be accepted and will be cancelled.
Please go to www.cybergrants.com/pfizer/knowledge and sign in. First-time users should click “Create
▪
your password”. [Note: there are individual portals for each grant application type. Please be sure to
use the URL above.]
Click the “Start A New Knowledge Gap Application" button.
▪
Requirements for submission:
▪
Complete all required sections of the online application
▪
3

IMPORTANT: Upload proposal (see Appendix) in the General RFP Submission field.
▪
In the application:
▪
For the question “Competitive Grant?” select “Yes”
▪
Select the following Primary Area of Interest: Dermatology - Alopecia Areata - KG
▪
Select the following Competitive Grant Program Name: 2025 I&I US Alopecia Areata KG
▪
IMPORTANT: Be advised applications submitted after the due date will not be reviewed.
▪
Questions:
If you encounter any technical difficulties with the website, please click here or the “Technical
▪
Questions” link at the bottom of the page in Cybergrants.
Please click here to view “Frequently Asked Questions” regarding the Competitive Grant Program.
▪
If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Talita
▪
Honorato-Rzeszewicz (talita.honorato-rzeszewicz@pfizer.com), with the subject line “2025 I&I US
Alopecia Areata KG.”
Grant Agreements:
If your grant is approved, your institution will be required to enter into a written grant agreement with
▪
Pfizer. Please click here to view the core terms of the agreement.
Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed
▪
unless a genuine conflict exists as between applicable law and the terms of the relevant grant
agreement. Applicant is encouraged to share the core terms with counsel for approval prior to
submitting an application.
Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal,
▪
payment of grant funding may only be paid to the grantee organization.
This RFP is supported by Pfizer Inc. and, if approved the payment will be issued by a Pfizer US based
▪
legal entity.
Review and Approval Process:
Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant
▪
decisions.
Mechanism by which Applicants will be Notified:
All applicants will be notified via email by the dates noted above.
▪
Applicants may be asked for additional clarification during the review period.
▪
About Pfizer Grants:
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality
improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with
Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted general Request for Proposal (RFP) that
provides detail regarding a general area of interest, sets timelines for review and approval, and uses an
internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application
addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible
for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must
not be involved in any aspect of project development, nor the conduct of the independent education program.
4

Appendix
General RFP Submission Requirements
Applications will be accepted via the online portal listed in the How to Submit section. Project Proposals
should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit
exclusive of references. When uploading your Project Proposal please ensure it addresses the following
sections:
Goals and Objectives
• Briefly state the overall goal of the project.
• List the objectives you plan to meet with your project, in terms of learning and expected outcomes.
Needs Assessment for the Project
Include a description of your organization’s needs assessment for this proposed project which may
•
include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on
gap analyses or relevant patient-level data that informs the stated objectives) in your target area.
Target Audience
Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit
•
from the project outcomes. Describe the overall population size as well as the size of your sample
population.
Project Design and Methods
Describe the planned project, the educational approach, and the way the planned methods address the
•
established need.
Innovation
Explain what measures you have taken to assure that this project is original and does not duplicate other
•
projects or materials already developed. Describe how this project builds upon existing work, pilot
projects, or ongoing projects developed either by your institution or other institutions.
Evaluation and Outcomes
In terms of the metrics used for the needs assessment, describe how your organization will determine if
•
the gap was addressed for the target group. Identify the sources of data your organization anticipates
using to make the determination. Describe how your organization is expected to collect and analyze the
data.
• Explain the method used to control for other factors outside this project (e.g., use of a control group or
comparison with baseline data). Quantify the amount of change expected from this project in terms the
target audience. Describe how your organization will determine if the target audience was fully engaged in
the project.
Dissemination Plan
• Describe how the project may have extended benefit beyond the grant. Will the teaching materials be
made available to others to use? Will there be tools or resources that are made publicly available beyond
the initial project. Describe how the project outcomes might be broadly disseminated.
Anticipated Project Timeline
• Provide an anticipated timeline for your project including project start/end dates.
5

Additional Information
If there is any additional information you feel Pfizer should be aware of concerning the importance of this
•
project, please summarize here.
Organization Detail
Describe the attributes of the institutions / organizations / associations that will support and facilitate the
•
execution of the project and the leadership of the proposed project. Articulate the specific role of each
partner in the proposed project.
Budget Detail
• Please include a budget narrative that describes in greater detail the line items specified in the budget
submitted within the application.
• While estimating your budget please keep the following items in mind:
• Independent Medical Education Grants awarded by Pfizer cannot be used to purchase therapeutic
assets (prescription or non-prescription).
• Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer. Please
click here for details. General organizational running costs such as legal fees, insurance, heating, and
lighting etc. should be included in an Institutional Overhead (if required). These costs are not specific to
a grant request and therefore, should not appear as line items in budgets. However, costs that are
specific to the study (e.g., some countries require insurance to be taken out on a per-study basis for
clinical research) would be acceptable to be included as line items.
Required Documents
• Project Plan/Proposal or Meeting Agenda
6